News

Harbour BioMed will work alongside BMS to progress and expedite the programmes aimed at the discovery of the antibodies. Harbour BioMed, in exchange, is eligible to obtain payments

The company’s plans are expected to increase the capacity for injectable drug products. The expansion, scheduled to commence in early 2026, will add around 300,000ft² of purpose-built space

The expansion is targeted at individuals for whom topical corticosteroids are not sufficient or appropriate. The European regulator has accepted the application for review. The submission is based

The investment values Swixx at more than €1.5bn ($1.76bn). Swixx operates as a commercialisation platform for pharma companies, focusing on markets where those companies have chosen not to

Rett syndrome is a rare neurodevelopmental disorder that progresses through four stages. The formulation is intended to treat the condition in adult and paediatric patients aged two years

Sobi will purchase for Arthrosi Skr9.1bn ($950m) in cash. Additional payments of up to Skr5.3bn ($550m) may be made based on clinical, regulatory and sales milestones. The acquisition

The approval marks the first new treatment for the adult population with PPF in more than five years, offering a new alternative for those with this life-threatening lung

This next-generation central nervous system (CNS)-penetrant will be developed by Bleecker Bio, a newly established subsidiary of Formation. Lynk Pharmaceuticals will obtain a minority equity stake in Bleecker,

The approvals mark the fourth and fifth clearances for the company in the country in 2025. Qfitlia is the antithrombin-lowering therapy indicated for routine prophylaxis in individuals with